

DESCRIPTION


Species Reactivity	Mouse/Rat
Specificity	Detects mouse and rat Apolipoprotein H/ApoH in Western blots and detects recombinant mouse Apolipoprotein H/ApoH in direct ELISAs. In direct ELISAs, approximately 40% cross-reactivity with recombinant human Apolipoprotein H/ApoH is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse Apolipoprotein H/ApoH Gly20-Cys345 Accession # Q01339
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	0.25 µg/mL	See Below

DATA



PREPARATION AND STORAGE

Reconstitution	Sterile PBS to a final concentration of 0.2 mg/mL.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Apolipoprotein H (ApoH), also known as β 2-Glycoprotein I/ β 2-GPI, is a variably glycosylated member of the complement control superfamily of proteins with a molecular weight of approximately 50 kDa (1, 2). Mature mouse ApoH consists of four tandem Sushi/SCR repeats followed by one Sushi-like repeat (3, 4). Mature mouse ApoH shares 76% and 42% aa sequence identity with human and rat ApoH, respectively. Hepatocyte-derived ApoH binds directly to negatively charged phospholipids (5). It circulates as a component of lipoprotein particles and as a lipid-free serum protein (6). ApoH also associates with liposomes and apoptotic cell debris, thereby enabling their renal clearance *via* Megalin uptake (7, 8). Circulating levels of ApoH are positively correlated with triglyceride-rich lipoprotein (VLDL) components in type II diabetes (9). ApoH inhibits thrombosis by blocking the activation of Coagulation Factor XI but also shows procoagulant activity by inhibiting the activation of Protein C (10, 11). ApoH can be cleaved by Plasmin at Lys317-Thr318, an action that is enhanced by heparin (12, 13). ApoH cleavage reduces its ability to bind phospholipids and inhibit Factor XI activation but confers the ability to bind Plasminogen (10, 12, 14). Cleaved ApoH also demonstrates antiangiogenic activity, whereas intact ApoH does not (14). The production of antibodies against ApoH is a hallmark of Antiphospholipid Syndrome (APS), an autoimmune disorder that leads to hypercoagulability and recurrent miscarriages (15). ApoH binds to the surface antigen of Hepatitis B Virus and is associated with the development of HBV-induced hepatocellular carcinoma (6, 16).

References:

1. Crook, M.A. *et al.* (2010) *Atherosclerosis* **209**:32.
2. Miyakis, S. *et al.* (2004) *Thromb. Res.* **114**:335.
3. Nonaka, M. *et al.* (1992) *Genomics* **13**:1082.
4. Lozier, J. *et al.* (1984) *Proc. Natl. Acad. Sci.* **81**:3640.
5. Wurm, H. (1984) *Int. J. Biochem.* **16**:511.
6. Mehdi, H. *et al.* (1994) *J. Virol.* **68**:2415.
7. Chonn, A. *et al.* (1995) *J. Biol. Chem.* **270**:25845.
8. Moestrup, S.K. *et al.* (1998) *J. Clin. Invest.* **102**:902.
9. Castro, A. *et al.* (2010) *Atherosclerosis* **209**:201.
10. Shi, T. *et al.* (2004) *Proc. Natl. Acad. Sci.* **101**:3939.
11. Mori, T. *et al.* (1996) *Thromb. Haemost.* **75**:49.
12. Hunt, J. *et al.* (1993) *Proc. Natl. Acad. Sci.* **90**:2141.
13. Guerin, J. *et al.* (2002) *J. Biol. Chem.* **277**:2644.
14. Sakai, T. *et al.* (2007) *Am. J. Pathol.* **171**:1659.
15. Adams, M. (2008) *Semin. Thromb. Haemost.* **34**:251.
16. Jing, X. *et al.* (2010) *J. Cancer Res. Clin. Oncol.* **16**:1671.